The GREM1-neutralizing antibody–treated group showed a trend toward prolonged overall survival and a trend toward decreased tumor growth, although the groups, as dosed in this study, did not show significant differences in survival (Supplementary Figure 20E and F). This evidence concerns the gene GREM1 and neoplasm.